This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Venepalli N, Rezvani K, Mielke S, Savani BN . Role of allo-SCT for CML in 2010. Bone Marrow Transplant 2010; 45: 1579–1586.
Milojkovic D, Nicholson E, Apperley JF, Holyoake TL, Shepherd P, Drummond MW et al. Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica 2010; 95: 224–231.
Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009; 27: 6041–6051.
Hehlmann R, Berger U, Pfirrmann M, Heimpel H, Hochhaus A, Hasford J et al. Drug treatment is superior to allografting as first line therapy in chronic myeloid leukemia. Blood 2007; 109: 4686–4692.
Saussele S, Lauseker M, Gratwohl A, Heim D, Beelen DW, Döhner H et al. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 2010; 115: 1880–1885.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Saußele, S., Hehlmann, R., Gratwohl, A. et al. Outcome of patients with CML after SCT in the era of tyrosine kinase inhibitors. Bone Marrow Transplant 47, 304 (2012). https://doi.org/10.1038/bmt.2011.70
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2011.70